Consequently, this study provides a potent non-invasive tool for predicting EGFR gene mutation status and HER2 overexpression in adenocarcinoma brain metastases, thereby greatly enhancing patient prognosis. The gene discussed is ERBB2; the disease is adenocarcinoma.